YAP1 and neuroblastoma: The lack of genomic YAP alterations (i.e., mutations, amplification) and our finding of increased YAP expression following a single cycle of cytotoxic therapy in RAS-mutated neuroblastoma in vivo, support that chemotherapy-induced damage may upregulate YAP in the tumor and may also explain the presence of increased YAP in post-chemotherapy relapsed primary neuroblastoma [51].